Stanford Center for Inherited Cardiovascular Disease

Recent News


Praluent looks cheap to those with extreme cholesterol (NY Times, July 2015)

Federal Panel Backs Approval of New Drug to Fight Heart Attacks (NY Times, June 2015)

Key to the Heart (Genome, April 2015)

Familial Hypercholesterolemia: Underdiagnosed, risks underappreciated; mew treatments on horizon (Cardiology Today, Feb 2015)

March 2014

Stanford Hospital Launches Clinical Genome Program

February 2014

Drs. Knowles and Wheeler represented Stanford at at an international symposium held at Genome Quebéc on February 13th, 2014 in partnership with the Grand défi Pierre Lavoie (a well known Canadian charity focused on improving health especially among youth). Dr. Knowles gave an invited presentation entitled "How we can (and will) use genetics to improve cardiovascular health".  Among other things the presentation highlighted the key role genetics has played in identifying the genetic basis of disease, making smarter decisions about drug discovery and enhancing the ability to pursue family-based screening for certain potentially dangerous conditions such as hypertrophic cardiomyopathy and familial hypercholesterolemia.  Both Drs. Knowles and Wheeler participated in a panel discussion with other international experts such as Drs. Jacques Genest (Professor and Chair in Medicine, McGill) and Sonia Anand (Professor of Medicine and Epidemiology, McMaster).  

Past News

Medicine for the rich is about to get cheap enough for regular people (Wired, February 2013)


Joshua Knowles, MD, PhD-FH Foundation DirectorJoshua Knowles, MD, PhD - Chief Medical Officer, FH Foundation

Familial hypercholesterolemia underdiagnosed, undertreated worldwide (, September 2013)

How to Raise a Disease's Profile (Stanford Medicine, November 2013)




iPSC Research Project:

NHLBI grants will fund use of iPS cells to study insulin resistance and pulmonary hypertension.

CAD Genetics Trial:

Researchers aim to see if patients are helped by genetic tests.


Research within the SCICD (in full) is broad ranging and reflects the depth of Stanford’s investment in genetics and inherited cardiovascular disease. A selection of recent work is linked here:

Randomized Trial of Personal Genomics for Preventive Cardiology : Design and Challenges


Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence

Circulation:  Cardiovascular Genetics

Gene coexpression network topology of cardiac development, hypertrophy and failure

Curr Opin Cardiol

The concept of ventricular reserve in heart failure and pulmonary hypertension: an old metric that brings us one step closer in our quest for prediction

J Cell Biol

BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways


Clinical assessment incorporating a personal genome


Challenges in the clinical application of whole-genome sequencing


Chromatin regulation by Brg1 underlies heart muscle development and disease


A new era in clinical genetic testing for hypertrophic cardiomyopathy

Nature Genetics

Genome-wide meta-analyses identify multiple loci associated with smoking behavior


Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies

Genome Biology

Characterizing the admixed African ancestry of African Americans

Human Molecular Genetics

Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study




Footer Links: